3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
24
NIH
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
9
Lymphoma, Follicular
4
Lymphoma, Large B-Cell, Diffuse
3
Recurrence
2
Graft vs Host Disease
2
Ulcer
1
Stomatitis
1
Prostatic Neoplasms
1
Peritoneal Neoplasms
1
Oral Ulcer
1
Metastatic Castration-Resistant Prostate Cancer
1
Melanoma
1
Lymphoma, B-Cell
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Intestinal Obstruction
1
Colitis, Ulcerative
1
Colitis
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Rituximab
82
venetoclax
56
ibrutinib
46
obinutuzumab
43
Bendamustine Hydrochloride
40
idelalisib
30
Cyclophosphamide
29
acalabrutinib
28
fludarabine
27
Chlorambucil
27
pirtobrutinib
18
ublituximab
16
ofatumumab
16
zanubrutinib
14
umbralisib
14
Lenalidomide
11
fludarabine phosphate
9
Alemtuzumab
9
navitoclax
7
duvelisib
7
Azacitidine
5
lumiliximab
4
aflibercept
4
TRU 016
4
Interleukin-2
4
BI 836826
4
ARQ531
4
tafasitamab
3
motexafin gadolinium
3
dinaciclib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
Methylprednisolone
×
Clear all
NCT06970743
2026-05-11
CaDAnCe-303
BeOne Medicines
Phase 3
Recruiting
150 enrolled